

Benlysta® (belimumab) – Expanded indication

- On July 27, 2022, <u>GSK announced</u> the <u>FDA approval</u> of <u>Benlysta (belimumab)</u>, for the treatment of patients aged 5 years and older with active lupus nephritis who are receiving standard therapy.
 - Benlysta was previously approved for this indication for adults only.
- Benlysta is also approved for the treatment of patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy.
- The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Use of Benlysta is not recommended in this situation.
- Use of Benlysta in pediatric patients with active lupus nephritis is based on the extrapolation of efficacy from the intravenous study in adults (n = 224) with active lupus nephritis, and supported by pharmacokinetic data from intravenous studies in adults (n = 224) with active lupus nephritis and from pediatric patients (n = 53) with SLE. Estimated belimumab exposures for pediatric patients were comparable to adults with active lupus nephritis.
- The recommended intravenous dosage of Benlysta for pediatric patients with lupus nephritis is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter.
 - Benlysta should be administered by healthcare providers prepared to manage anaphylaxis.
 - Refer to the Benlysta drug label for dosing for its other uses.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.